Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Goldman, J., Lye, D., Hui, D., Marks, K., Bruno, R., Montejano, R., Spinner, C., Galli, M., Ahn, M., Nahass, R., Chen, Y., SenGupta, D., Hyland, R., Osinusi, A., Cao, H., Blair, C., Wei, X., Gaggar, A., Brainard, D., Towner, W., Muñoz, J., Mullane, K., Marty, F., Tashima, K., Diaz, G., & Subramanian, A. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2015301
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19